Thrivent Financial for Lutherans reduced its holdings in Vericel Co. (NASDAQ:VCEL - Free Report) by 10.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 367,841 shares of the biotechnology company's stock after selling 45,126 shares during the quarter. Thrivent Financial for Lutherans owned about 0.75% of Vericel worth $20,198,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in VCEL. William Blair Investment Management LLC boosted its holdings in Vericel by 66.3% in the fourth quarter. William Blair Investment Management LLC now owns 1,258,416 shares of the biotechnology company's stock valued at $69,100,000 after acquiring an additional 501,736 shares in the last quarter. Cibc World Markets Corp bought a new stake in shares of Vericel during the 4th quarter valued at about $252,000. Envestnet Portfolio Solutions Inc. purchased a new position in shares of Vericel during the fourth quarter valued at about $261,000. Natixis Advisors LLC raised its stake in Vericel by 7.1% in the fourth quarter. Natixis Advisors LLC now owns 38,902 shares of the biotechnology company's stock worth $2,136,000 after buying an additional 2,564 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in Vericel by 6.7% in the fourth quarter. Swiss National Bank now owns 96,500 shares of the biotechnology company's stock worth $5,299,000 after buying an additional 6,100 shares during the period.
Vericel Stock Performance
Shares of VCEL stock traded up $0.02 on Tuesday, reaching $47.96. The stock had a trading volume of 346,495 shares, compared to its average volume of 374,022. Vericel Co. has a 1 year low of $39.12 and a 1 year high of $63.00. The stock has a market cap of $2.40 billion, a P/E ratio of 799.47 and a beta of 1.78. The company has a 50 day simple moving average of $54.16 and a 200 day simple moving average of $51.73.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on VCEL. BTIG Research increased their target price on Vericel from $56.00 to $66.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. Stephens reiterated an "overweight" rating and issued a $65.00 price objective on shares of Vericel in a report on Wednesday, January 15th. StockNews.com raised Vericel from a "sell" rating to a "hold" rating in a research report on Saturday, March 8th. HC Wainwright reaffirmed a "buy" rating and issued a $60.00 target price on shares of Vericel in a research report on Friday, February 28th. Finally, Truist Financial reissued a "buy" rating and set a $61.00 price target (down from $67.00) on shares of Vericel in a research report on Monday, March 3rd. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $62.29.
Check Out Our Latest Report on VCEL
Insider Activity at Vericel
In other news, CEO Dominick Colangelo sold 26,592 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $45.78, for a total value of $1,217,381.76. Following the transaction, the chief executive officer now directly owns 259,997 shares in the company, valued at $11,902,662.66. The trade was a 9.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert L. Md Zerbe sold 2,500 shares of the business's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total value of $156,250.00. Following the completion of the transaction, the director now directly owns 26,595 shares in the company, valued at approximately $1,662,187.50. This represents a 8.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,092 shares of company stock worth $1,683,582. Corporate insiders own 5.20% of the company's stock.
Vericel Profile
(
Free Report)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Featured Articles
Before you consider Vericel, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vericel wasn't on the list.
While Vericel currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
